Resources from the same session
809MO - Efficacy and safety results from the phase II study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma
Presenter: Yuqin Song
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Slides
Webcast
810MO - Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: A phase l/II study
Presenter: Zhiming Li
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Slides
Webcast
811MO - An exploratory study to assess the safety, immunogenicity, and preliminary anti-tumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with NK/T cell lymphoma
Presenter: Xiangrong Song
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Slides
Webcast
812MO - Initial results of the multicenter phase II trial of a novel hypofractionated low-dose radiotherapy for indolent non-Hodgkin lymphoma
Presenter: Xinyue Wang
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Slides
Webcast
813MO - Phase I trial of a personalized multi-peptide vaccine combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients
Presenter: Christopher Hackenbruch
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Webcast
815MO - A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): Preliminary analysis on efficacy and safety
Presenter: Jia-Dai Xu
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Slides
Webcast
816MO - Two hematological precursors and their impact on hematological malignancies
Presenter: Nicholas Boddicker
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant 813MO, 814MO, 815MO and 816MO
Presenter: Annarita Conconi
Session: Mini oral session 2: Haematological malignancies
Resources:
Slides
Webcast